All In Biotech

Drug Trial Radar · NCT07680439

Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).

A Phase 2 Pivotal Study of BCB-276, a B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingTitle says "pivotal". This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

75

Planned (sponsor's estimate)

Start

Sep 4, 2026

Primary completion

Oct 2028

Study completion Jul 2030

Sponsor

Lead sponsor
BrainChild Bio, IncIndustry
Sponsor type
Industry
First posted
Jul 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 year, up to 26 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate BCB-276, an investigational B7-H3-targeted Chimeric Antigen Receptor (CAR) T cell therapy, in children and young adults with diffuse intrinsic pontine glioma (DIPG). DIPG is a rare and aggressive brain tumor with limited treatment options. CAR T cell therapy uses a patient's own immune cells that are changed in a laboratory to recognize and attack cancer cells. The purpose of this study is to determine whether BCB-276, when given after completion of standard radiation therapy, is safe and can improve survival for patients with DIPG. To participate, individuals must be between 1 and 26 years of age when they join the study, have a diagnosis of DIPG, and enroll for treatment within 6 weeks of completing initial radiation therapy. Participants must not have received prior anti-cancer therapy beyond radiation with or without temozolomide prior to joining this study. BCB-276 is administered intraventricularly (into the fluid around the brain), which requires placement of a catheter for treatment. BCB-276 is given every 2 weeks at a research center over a period of several months (approximately 7-8 months). Participation includes travel to a study site, procedures to support treatment administration, sample collection, and ongoing monitoring for safety and effectiveness, with follow-up visits lasting up to about 2 years.

Conditions

  • Diffuse Intrinsic Pontine Glioma
  • DIPG
  • Brain Tumor
  • CNS Tumor
  • Central Nervous System Tumor
  • Pediatric Cancer
  • Adult Cancer Patients
  • CNS Tumor, Childhood
  • CNS Tumor, Adult
  • Brainstem Glioma
  • Diffuse Midline Glioma
  • DMG

Interventions

  • BCB-276Biological

    Following completion of standard radiation therapy, eligible participants with DIPG will undergo leukapheresis, a procedure to collect white blood cells used to manufacture BCB-276, an autologous CAR T cell therapy made from the participant's own immune cells designed to target B7-H3. All eligible participants will receive up to 15 intraventricular administrations of BCB-276 every 2 weeks for an approximate total duration of 30 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall SurvivalTime frame: Overall Survival (OS) as defined as time from the date of enrollment to death from any cause (up to 24 months from date of enrollment).

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Children's Hospital Los Angeles

    Los Angeles, California · Not yet recruiting

  • Children's Healthcare of Atlanta

    Atlanta, Georgia · Recruiting

  • Lurie Children's Hospital

    Chicago, Illinois · Recruiting

  • Nationwide Children's Hospital

    Columbus, Ohio · Not yet recruiting

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania · Recruiting

  • Seattle Children's Hospital

    Seattle, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.